<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758339</url>
  </required_header>
  <id_info>
    <org_study_id>ONT-380-008</org_study_id>
    <nct_id>NCT03758339</nct_id>
  </id_info>
  <brief_title>A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [¹⁴C]-Tucatinib Following a Single Oral Dose in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cascadian Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib
      while it is still in the body. Healthy participants will get one dose of tucatinib by mouth.
      Patients will be monitored for 8-14 days after they take the dose of tucatinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the absorption, metabolism, and excretion of tucatinib in healthy
      individuals. Participants will receive one oral dose of tucatinib and will be followed for
      8-14 days after the dose is received.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2017</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) from time 0 to infinity (AUC[0-inf])</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to last quantifiable concentration</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed concentration</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome parameter for tucatinib derived from the whole blood and plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome parameter for tucatinib derived from the whole blood and plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC[0-inf] plasma tucatinib/total radioactivity ratio</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>AUC[0-inf] of plasma tucatinib relative to AUC[0-inf] of plasma total radioactivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC[0-inf] blood/plasma ratio</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>AUC[0-inf] of whole blood total radioactivity to AUC[0-inf] of plasma total radioactivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted in urine (Aeu)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome endpoint of tucatinib, ONT-993, and total radioactivity derived from urine collections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Aeu</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome endpoint of tucatinib, ONT-993, and total radioactivity derived from urine collections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage excreted in urine (Feu)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome endpoint of tucatinib and total radioactivity derived from urine collections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Feu</measure>
    <time_frame>Up 14 days</time_frame>
    <description>PK outcome endpoint of tucatinib and total radioactivity derived from urine collections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome endpoint of tucatinib derived from urine collections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted in feces [Aef]</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome endpoint of total radioactivity derived from feces collection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Aef</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome endpoint of total radioactivity derived from feces collection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage excreted in feces [Fef]</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome endpoint of total radioactivity derived from feces collection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Fef</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PK outcome endpoint of total radioactivity derived from feces collection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of tucatinib and its metabolites eliminated in urine and feces</measure>
    <time_frame>Up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of tucatinib and its metabolites in plasma</measure>
    <time_frame>Up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tucatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tucatinib</intervention_name>
    <description>Single dose of 300 mg of [¹⁴C]-tucatinib containing approximately 150 μCi of [¹⁴C] radioactivity</description>
    <arm_group_label>Tucatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health, determined by no clinically significant findings from medical history,
             physical examination, 12-lead ECG, vital signs measurements, or lab evaluations

          -  Body mass index (BMI) between 18 and 32 kg/m²

          -  Weight between 50 and 100 kg

          -  Females must be of non-childbearing potential

          -  Males must agree to use contraception

        Exclusion Criteria:

          -  History of any metabolic, allergic, dermatological, hepatic, renal, hematological,
             pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or
             psychiatric disorder

          -  Any condition affecting drug absorption

          -  History of hypersensitivity or allergy to any drug compound, food, or other substance

          -  History of alcoholism or drug/chemical abuse within 2 years

          -  Use of prescription products within 28 days prior to check in

          -  Use of tobacco- or nicotine-containing products within 3 months prior to check in
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Vo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cascadian Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>November 28, 2018</last_update_submitted>
  <last_update_submitted_qc>November 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

